bleximenib + venetoclax + azacitidine

Bleximenib + venetoclax + azacitidine is an investigational, orally administered combination therapy under development for the treatment of acute myeloid leukemia (AML), particularly in patients harboring *KMT2A* rearrangements or NPM1 mutations. - **Bleximenib (JNJ-75276617)** is a highly selective small molecule inhibitor of menin, aimed at disrupting the oncogenic interaction between menin and KMT2A-fusion or mutant NPM1 proteins, which are critical drivers of leukemogenesis in specific AML subtypes. - **Venetoclax** is an oral small molecule BCL-2 (B-cell lymphoma 2) inhibitor that promotes apoptosis in leukemia cells. - **Azacitidine** is a hypomethylating agent that incorporates into DNA and RNA, inhibiting DNA methyltransferase and inducing cytotoxicity in abnormal hematopoietic cells. This triplet combination is being evaluated in patients with newly diagnosed, intensive chemo-ineligible AML, and relapsed/refractory AML. Early phase clinical data demonstrate that the triplet has promising antileukemic activity, with manageable safety, and may provide a superior therapeutic effect compared to doublet therapies, especially in genetically defined AML with poor prognosis.

Other names

VENAZA